CFA
LABP

Carroll Financial Associates’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

Carroll Financial Associates’s Portfolio LABP Stock Details LABP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$2K Buy
41
+2
+5% +$210 ﹤0.01% 1515
2021
Q3 		$5K Buy
39
+34
+680% +$4.41K ﹤0.01% 1388
2021
Q2 		$0 Buy
+5
New +$557 ﹤0.01% 1895

Other funds holding LABP

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Carroll Financial Associates's LABP Position: Q4 2021 in Review

Carroll Financial Associates increased its Landos Biopharma, Inc. Common Stock (LABP) stake by 5.1% in Q4 2021, buying an estimated $210 and bringing the position to 41 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #1515.

Carroll Financial Associates first reported a position in LABP in Q2 2021 and has held it in 3 quarters since. The position peaked at $5K in Q3 2021. 40 funds tracked by Wall St. Rank hold LABP as of Q4 2021.

  • Carroll Financial Associates held 41 shares of Landos Biopharma, Inc. Common Stock worth $2K as of Q4 2021.
  • Carroll Financial Associates bought 2 Landos Biopharma, Inc. Common Stock shares in Q4 2021, an estimated $210.
  • Landos Biopharma, Inc. Common Stock made up ﹤0.01% of Carroll Financial Associates's portfolio in Q4 2021, its #1515 holding.
  • Carroll Financial Associates first reported a position in Landos Biopharma, Inc. Common Stock in Q2 2021 and has held it in 3 quarters since.
  • Carroll Financial Associates's Landos Biopharma, Inc. Common Stock position peaked at $5K in Q3 2021.
  • 40 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q4 2021.

Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.